Segment Reporting

6 Months Ended

Jun. 30, 2024

Segment Reporting [Abstract]

Segment Reporting

13.   Segment Reporting. We report our operations in two operating segments: cardiovascular and endoscopy. Our cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and OEM. Within these product categories, we sell a variety of products, including cardiology and radiology devices (which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases), as well as embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, breast cancer localization and guidance, biopsy, and interventional oncology and spine devices. Our endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures. Our chief operating decision maker is our Chief Executive Officer. We evaluate the performance of our operating segments based on net sales and income from operations.

Financial information relating to our reportable operating segments and reconciliations to the consolidated totals for the three and six-month periods ended June 30, 2024 and 2023, were as follows (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2024		2023		2024		2023
Net sales
Cardiovascular	$	327,815	$	311,275	$	641,189	$	599,251
Endoscopy		10,188		8,781		20,322		18,370
Total net sales		338,003		320,056		661,511		617,621
Income from operations
Cardiovascular		42,912		26,464		75,819		50,398
Endoscopy		3,034		2,348		6,049		4,797
Total income from operations		45,946		28,812		81,868		55,195
Total other expense — net		(103)		(3,912)		(1,677)		(4,795)
Income tax expense		10,117		4,655		16,225		9,452
Net income	$	35,726	$	20,245	$	63,966	$	40,948